Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04129931 · ClinicalTrials.gov registry record · Phase 2
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
A Phase 2 study of Asthma, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 395
- Enrollment target
- 20
- Study locations
NCT04129931 is a Phase 2 study of Asthma that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 395 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT04129931, a Phase 2 study of Asthma, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 395 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week washout.
Conditions Studied
Interventions
- DRUG Imatinib Mesylate
- DRUG Clazakizumab
- DRUG MCT
- DRUG Broncho-Vaxom
- DRUG Cavosonstat
Study Locations (20)
Illinois
- University of Illinois at Chicago - Chicago
- Ann & Robert H. Lurie Children's Hospital - Chicago
- Northwestern Universtiy - Chicago
- Rush University - Chicago
- University of Chicago - Chicago
California
- University of California Davis - Sacramento
- University of California San Diego: Airway Research & Clinical Trials Center - San Diego
- University of California San Diego: La Jolla Altman Clinical Translation Research Institute - San Diego
- University of California San Francisco - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
- University of Colorado Denver - Aurora
- National Jewish Health - Denver
Arizona
- Mayo Clinic Scottsdale - Scottsdale
- University of Arizona Tucson - Tucson
Massachusetts
- Boston Children's Hospital - Boston
- Brigham and Women's Hospital - Boston
Connecticut
- Yale University - New Haven
Florida
- University of South Florida - Tampa
Indiana
- Riley Hospital for Children - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2025-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04129931
The ClinicalTrials.gov registry entry for NCT04129931 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 395 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (75% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 5 interventions - of which Imatinib Mesylate is the first listed.
NCT04129931 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Illinois, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04129931 about?
NCT04129931 is a clinical study titled "PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study". The primary objective of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week washout.
What is the current status of trial NCT04129931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 395 participants. The study started on 2019-12-19. Estimated completion is 2025-03-19.
What conditions does trial NCT04129931 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT04129931?
The interventions under investigation include: Imatinib Mesylate (DRUG), Clazakizumab (DRUG), MCT (DRUG), Broncho-Vaxom (DRUG), Cavosonstat (DRUG).
Who is sponsoring clinical trial NCT04129931?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04129931 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.